Abstract
Pneumonia causes a significant burden of disease worldwide. Although all populations are at risk of pneumonia, those at extremes of age and those with immunosuppressive disorders, underlying respiratory disease, and critical illness are particularly vulnerable. Although clinical practice guidelines addressing the management and treatment of pneumonia exist, few of the supporting studies focus on the crucial contributions of the host in pneumonia pathogenesis and recovery. Such essential considerations include the host risk factors that lead to susceptibility to lung infections; biomarkers reflecting the host response and the means to pursue host-directed pneumonia therapy; systemic effects of pneumonia on the host; and long-term health outcomes after pneumonia. To address these gaps, the Pneumonia Working Group of the Assembly on Pulmonary Infection and Tuberculosis led a workshop held at the American Thoracic Society meeting in May 2018 with overarching objectives to foster attention, stimulate research, and promote funding for short-term and long-term investigations into the host contributions to pneumonia. The workshop involved participants from various disciplines with expertise in lung infection, pneumonia, sepsis, immunocompromised patients, translational biology, data science, genomics, systems biology, and clinical trials. This workshop report summarizes the presentations and discussions and important recommendations for future clinical pneumonia studies. These recommendations include establishing consensus disease and outcome definitions, improved phenotyping, development of clinical study networks, standardized data and biospecimen collection and protocols, and development of innovative trial designs.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1087-1097 |
| Number of pages | 11 |
| Journal | Annals of the American Thoracic Society |
| Volume | 18 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2021 |
Funding
Author Disclosures: S.E.E. had a financial stake, commercialized intellectual property (PUL-042) and U.S. patent 8,883,174 with Pulmotect. N.D. served as a consultant for Biofire, Merck; on a data and safety monitoring board for Clinipace, Contrafect, Theravance. B.C. served on a steering committee for Roche; received research support from BioMerieux, Cepheid, National Natural Foundation of China, Peking Union Medical College Foundation. J.D.C. served as a consultant to Aradigm, AstraZeneca, Bayer, Chiesi, GlaxoSmithKline, Grifols, Insmed Novartis, Zambon; on an advisory committee for Insmed; served as a speaker for Boehringer Ingelheim; received research support from AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Insmed, Novartis. J.C. served on an advisory committee for Bayer, as a speaker for Bayer, Pfizer; on a data and safety monitoring board for Aridis, Inotrem, Merck, Shionogi, Tigenix/Takeda; on an endpoint adjudication committee for Combacte Magnet; received research support from MedImmune. T.S.C. was an employee of MedImmune. A.H.C. served as a consultant for Bayer; was an employee of Aridis. C.F. served on an advisory committee for Abbott, Aurogen, MSD, Novartis, Pfizer; as a speaker for Abbott, AstraZeneca, Aurogen, Cipla, Pfizer, Sandoz. M.S.N. served on an advisory committee for Melinta, Nabriva, Paratek; served as a consultant for Abbvie, Fisher Diagnostics, Merck, Nabriva, Pfizer, Shinogi; received research support from Merck and Shionogi. J.R. served on an advisory committee for Achaogen, Nabriva, Paratek, Pfizer, The Medicines Company; as a consultant for Curetis, Pfizer; as a speaker for Amgen, The Medicines Company; received research support from Pfizer. Y.S. served as a speaker for AstraZeneca, Daiichi Sankyo, Kyorin, MSD, Nippon, Pfizer, Shionogi, Taisho Toyama. R.G.W. served on an advisory committee for Accelerate Diagnostics, Arsanis, Bayer, bioMerieux, Merck, Nabriva, Polyphor; as a
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
